Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-10-02FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc., resulting in an updated labeling/indica…
-
FDA approval · 2020-09-17FDA Approved: YONSA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for YONSA (abiraterone acetate) submitted by Sun Pharmaceutical Industries, Inc., updating the l…
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer [Phase 2]
Phase II study evaluating higher-dose abiraterone acetate in castration-resistant prostate cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-07Clinical Trial Update: Sequencing Abiraterone and Enzalutamide in mCRPC [Phase 2]
A Phase 2 trial update evaluating sequencing of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer has complete…
-
FDA approval · 2020-08-04FDA Approved: XTANDI — Original Application (Astellas Pharma US, Inc.)
FDA approves XTANDI (enzalutamide) under the original application NDA213674 for metastatic castration-resistant prostate cancer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-07-27Clinical Trial Update: SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation [Phase 1, Phase 2]
Clinical trial update for SC10914 monotherapy in metastatic castration-resistant prostate cancer with g/s BRCA mutation, covering Phase 1 an…
-
CLINICAL_TRIALS trial_result · 2020-07-22Clinical Trial Update: Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial update for pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC) with unclear status.
-
CLINICAL_TRIALS trial_result · 2020-06-01Clinical Trial Update: Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer [Phase 3]
Phase 3 trial evaluating enzalutamide with or without abiraterone and prednisone in castration-resistant metastatic prostate cancer; status …
-
FDA approval · 2020-05-18FDA Approved: ABIRATERONE ACETATE — Original Application (Dr. Reddys Laboratories Inc)
FDA approved Dr. Reddy's Laboratories Inc's original application for Abiraterone acetate, enabling a generic version of the cancer drug for …
-
CLINICAL_TRIALS trial_result · 2020-05-05Clinical Trial Update: A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) [Phase 2]
Phase 2 PET/CT imaging study in patients receiving enzalutamide for castration-resistant prostate cancer with bone metastases has completed …
-
FDA approval · 2020-03-05FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy [Phase 2]
Phase 2 study of abiraterone acetate in chemo-naive metastatic castration-resistant prostate cancer patients with prior diethylstilbestrol e…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA [Phase 2]
Phase 2 clinical trial evaluating biomarkers of androgen response and resistance in patients with castration-resistant prostate cancer.
-
FDA approval · 2019-12-16FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) from Astellas Pharma US, resulting in an updated label.
-
FDA approval · 2019-12-10FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for XOFIGO (Radium Ra-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc., markin…
-
CLINICAL_TRIALS trial_result · 2019-12-06Clinical Trial Update: 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial update for 177Lu-PSMA-I&T radioligand therapy in metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2019-11-14Clinical Trial Update: Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients [Phase 2]
Phase 2 trial evaluating natural dendritic cells for immunotherapy in chemo-naive metastatic castration-resistant prostate cancer has comple…
-
CLINICAL_TRIALS trial_result · 2019-11-04Clinical Trial Update: A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer [Phase 1, Phase 2]
A clinical trial update for Paclitaxel (Albumin-binding) in castration-resistant prostate cancer spanning Phase 1/2, with limited status inf…
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients [Phase 2]
Phase 2 clinical trial of the dual mTOR inhibitor MLN0128 in advanced metastatic castration-resistant prostate cancer has completed with res…
-
CLINICAL_TRIALS trial_result · 2019-10-21Clinical Trial Update: Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) [Phase 1]
Phase 1 trial update investigating enzalutamide and niraparib for metastatic castration-resistant prostate cancer (CRPC) has been terminated…
-
FDA approval · 2019-10-16FDA Approved: ABIRATERONE ACETATE — Original Application (NORTHSTAR RX LLC)
FDA approved the original ANDA for abiraterone acetate submitted by NorthStar RX LLC.
-
FDA approval · 2019-09-27FDA Approved: ABIRATERONE ACETATE — Original Application (Florida Pharmaceutical Products, LLC.)
FDA approved a generic version of abiraterone acetate under an original ANDA from Florida Pharmaceutical Products, LLC for metastatic castra…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
A clinical trial update reports a positive imaging study for distant metastases in patients with castration-resistant prostate cancer. The s…
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer [Phase 3]
Phase 3 trial update for Abiraterone Acetate in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 trial assessing TAK-700 in combination with docetaxel and prednisone for metastatic castration-resistant prostate cancer has com…